ARCHIVES

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

This article is from The Cancer Letter archive.

Vol. 33 No. 02 | January 19, 2007

Download PDF Visit The Full Archive

Related Articles

NCAB Gives Life To Three CBCCP Contractors Marked For Termination; Compromise “Reasonable” – DeVita

May 30, 1980

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

DCE Concepts Approved

June 27, 1986

NCI subsidy of $2 million paid major expenses of rescheduled meeting.

April 15, 2005

In Brief: Increased Output Can Hold Down High Let Cost, Kligerman says; No More Groups On The Block

March 18, 1977

ASC Survey Leads to Strategic Plan Development, Office In Washington

June 9, 1989